top of page
Tailored AI vs Generalist Models: A Federated Approach to Blood-Brain-Barrier Permeability
Qubigen’s recent study on tailored federated AI for blood-brain-barrier permeability prediction has now been featured by Diagnostics World News in an article exploring why specialized AI systems are outperforming generic foundation models in life sciences. One Size Fits Few: Where Tailored AI Tools Outpace Generic Options The feature highlights Qubigen’s findings that federated, client-adapted AI Engines can dramatically outperform generalist models when applied to real-world
Apr 305 min read
Qubigen Launches Collaborative Federated AI Antiviral Drug Design Project
Qubigen is pleased to announce the launch of a new collaborative Federated AI drug design project focused on the development of novel antiviral small molecules for emerging infectious diseases. This initiative reflects Qubigen’s commitment to shortening development timelines and advancing next-generation drug discovery through secure, collaborative AI technologies. Enabling Secure Multi-Party Drug Design with Qubigen’s FedAIDD This multi-party initiative consists of nonprofit
Apr 293 min read
Qubigen Announces a Collaboration with Viva Biotech in AI-Driven Drug Discovery
Qubigen is pleased to announce a new collaboration with Viva Biotech, a global leader in AI-enabled drug discovery. Through this partnership, we will actively explore areas where traditional computational tools fall short, notably in the domain of failed (‘dark’) reaction data. The collaboration brings together Viva Biotech’s advanced Artificial Intelligence Drug Discovery (AIDD) capabilities with Qubigen’s expertise in synthetic feasibility and reaction prediction AI models.
Apr 232 min read
bottom of page